
## What is claimed is:

## 1. A compound of Formula (I)



5

or a pharmaceutically acceptable salt or solvate thereof wherein

R<sup>1</sup> is H, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>thioalkyl, cyano, halo, C<sub>3-7</sub>cycloalkyl, -C<sub>1-6</sub>alkylene-C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl or C<sub>3-6</sub>alkynyl;

 $R^2$  is  $C(D)NR^3R^4$ , D'- D''( $R^3$ )( $R^4$ ) or  $CH_2N$   $R^3R^4$ D' is  $CH_2$  or a bond; D'' is C, C-OH or CH

15

20

10

wherein

said C is attached to R<sup>3</sup> by a single or double bond; said C is attached to R<sup>4</sup> by a single or double bond; provided that

C is not attached to both R<sup>3</sup> and R<sup>4</sup> by double bonds;

said CH is attached to R<sup>3</sup> and R<sup>4</sup> by single bonds; said C of C-OH is attached to R<sup>3</sup> and R<sup>4</sup> by single bonds;


D is O or S;

25

 $R^3$  and  $R^4$  are each independently selected from the group consisting of H,  $C_{1-6}$ alkyl,  $C_{1-6}$ haloalkyl,  $-C_{1-6}$ 6hydroxyalkyl,  $-C_{1-4}$ alkylene- $-C_{1-4}$ alkyl,  $-C_{1-3}$ alkylene- $-C_{1-4}$ 

		6thioalkyl, $-C_{2-6}$ alkylidene- $(C_{1-4}$ alkoxy) <sub>2</sub> , $C_{3-7}$ cycloalkyl, $-C_{1-6}$ alkylene- $C_{3-7}$ cycloalkyl, $C_{2-6}$ alkenyl, $C_{3-6}$ alkynyl, $-C_{1-6}$ alkylene-CN, $-C_{1-6}$ alkylene-heterocyclo and $-C_{1-6}$ alkylene-aryl;
5		wherein said aryl of said $-C_{1-6}$ alkylene-aryl is optionally substituted with one to three of the same or different substituents selected from the group consisting of fluoro, chloro, bromo, cyano, nitro, $C_{1-4}$ alkyl and $C_{1-3}$ alkoxy;
10		or  R <sup>3</sup> and R <sup>4</sup> together with the nitrogen to which they are attached form a five or six-membered heterocycle,
15		said heterocycle optionally containing one additional heteroatom selected from the group consisting of N, S and O; and
		said heterocycle optionally substituted with one or more groups selected from the group consisting of C <sub>1-6</sub> alkyl, C <sub>1-6</sub> alkoxy, aryl, -C <sub>1-4</sub> alkylene-aryl, pyridyl and halogen;
20		wherein said aryl of said -C <sub>1</sub> .  4alkylene-aryl is optionally substituted with one to three of the same or different substituents selected from the
25		group consisting of fluoro, chloro, bromo, cyano, nitro and $C_{1-3}$ alkoxy;
30	X is C; Y is C;	

A is



wherein

5  $X^1$  is N and is attached to X;

Y<sup>1</sup> is N and is attached to Y;

G is



10 wherein

Y<sup>2</sup> is CE<sup>1</sup> and is attached to Y<sup>1</sup>;

J is a bond;

 $Z^1$  is  $CE^3$  and is attached to Z;

wherein

15

E<sup>1</sup> and E<sup>3</sup> together form N(CH)<sub>3</sub>,

optionally substituted with halogen,

-CN,  $C_1$ - $C_4$ alkyl,  $C_3$ -

C<sub>6</sub>cycloalkyl, substituted or

unsubstituted phenyl,

hydroxy, C<sub>1</sub>-C<sub>4</sub>alkoxy, SH,

C<sub>1</sub>-C<sub>4</sub>thioalkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-

C<sub>4</sub>alkyl) or N(C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub>;

20

Z is N-V, wherein V is phenyl, 2-pyridyl or 3-pyridyl substituted with two to three of the same or different substitutents selected from the group consisting of C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-6</sub>thioalkyl, C<sub>1-4</sub>haloalkyl, halogen, N(C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub> and CN.

5

- 2. A compound according to claim 1 wherein V is phenyl or 3-pyridyl and is substituted with two to three of the same or different substitutents selected from the group consisting of C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-6</sub>thioalkyl, C<sub>1-4</sub>alkyl, and CN: said substituents attached at the
- 4haloalkyl, halogen, N(C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub> and CN; said substituents attached at the 2, 4 or 6-positions of said phenyl or said 3-pyridyl.
  - 3. A compound according to claim 1 wherein V is 2-pyridyl and is substituted with two of the same or different substitutents selected from the group consisting of C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-6</sub>thioalkyl, C<sub>1-4</sub>haloalkyl, halogen,
- N(C<sub>1</sub>-C<sub>4</sub>alkyl)<sub>2</sub> and CN; said substituents attached at the 3 and 5-positions of said 2-pyridyl.
  - 4. A compound according to claim 1 wherein  $R^1$  is  $C_{1-6}$ alkyl or  $C_{1-6}$ haloalkyl.
  - 5. A compound according to claim 1 wherein R<sup>1</sup> is methyl or trifluoromethyl.
  - 6. A compound according to claim 1 wherein R<sup>2</sup> is C(D)NR<sup>3</sup>R<sup>4</sup> and D is O.
- 7. A compound according to claim 1 wherein R<sup>2</sup> is CH<sub>2</sub>N R<sup>3</sup>R<sup>4</sup>.
  - 8. A compound according to claim 1 wherein R<sup>2</sup> is D'- D''(R<sup>3</sup>)(R<sup>4</sup>), D is a bond and D'' is C-OH.
  - 9. A compound according to claim 1 wherein R<sup>2</sup> is D'- D''(R<sup>3</sup>)(R<sup>4</sup>), D is a bond and D'' is C or CH.
- 25 10. A compound according to claim 1 wherein R³ and R⁴ are each independently selected from the group consisting of H, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, -C<sub>1</sub>. 6hydroxyalkyl, -C<sub>1-4</sub>alkylene-O-C<sub>1-4</sub>alkyl, -C<sub>1-3</sub>alkylene-C<sub>1-6</sub>thioalkyl, -C<sub>2-6</sub>alkylidene-(C<sub>1-4</sub>alkoxy)<sub>2</sub>, C<sub>3-7</sub>cycloalkyl, -C<sub>1-6</sub>alkylene-C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>alkynyl and -C<sub>1-6</sub>alkylene-CN.
- 30 11. A compound according to claim 1 wherein R<sup>3</sup> and R<sup>4</sup> together with the nitrogen to which they are attached form a five or six-membered heterocycle.
  - 12. A compound according to claim 1 wherein V is 2, 4, 6-trimethylphenyl.

- 13. A compound according to claim 1 wherein V is 2,4-dichlorophenyl.
- 14. A compound according to claim 1 wherein E<sup>1</sup> and E<sup>3</sup> together form N(CH)<sub>3</sub> optionally substituted with halogen, methoxy, methyl or nitrile.
- 15. A compound according to claim 1 wherein R<sup>2</sup> is CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, R<sup>3</sup> is ethyl or propyl, R<sup>4</sup> is –(CH<sub>2</sub>)<sub>2</sub>-phenyl, E<sup>1</sup> and E<sup>3</sup> together form N(CH)<sub>3</sub> optionally substituted with halogen, methoxy, methyl or nitrile.

5

- 16. A compound according to claim 1 wherein R<sup>2</sup> is CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, R<sup>3</sup> is ethyl or propyl, R<sup>4</sup> is –(CH<sub>2</sub>)<sub>2</sub>-phenyl, E<sup>1</sup> and E<sup>3</sup> together form N(CH)<sub>3</sub> optionally substituted with halogen.
- 17. A compound or pharmaceutically acceptable salt of solvate thereof selected from the group consisting of
   Ethyl-[2-methyl-8-(2,4,6-trimethyl-phenyl)-8H-1,3a,7,8-tetraaza-cyclopenta[α]inden-3-ylmethyl]-phenethyl-amine;
   Cyclobutylmethyl-[2-methyl-8-(2,4,6-trimethyl-phenyl)-8H-1,3a,7,8-tetraaza-cyclopenta[α]inden-3-ylmethyl]-propyl-amine;
  - [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8H-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-phenethyl-propyl-amine; [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[α]inden-3-ylmethyl]-cyclobutylmethyl-propyl-amine;
- [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8H-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-ethyl-phenethyl-amine;
  8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-3-(3-phenyl-pyrrolidin-1-ylmethyl)-8H-1,3a,7,8-tetraaza-cyclopenta[α]indene;
  Cyclopropylmethyl-propyl-[2-trifluoromethyl-8-(2,4,6-trimethyl-phenyl)-8H-
- 25 1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-amine;
  Phenethyl-[2-trifluoromethyl-8-(2,4,6-trimethyl-phenyl)-8H-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-(3,3,3-trifluoro-propyl)-amine;
  [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8H-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-phenethyl-propyl-amine;
- 30 [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8H-1,3a,7,8-tetraaza-cyclopenta[a]inden-3-ylmethyl]-ethyl-phenethyl-amine; and

- [8-(2-Chloro-4,6-dimethyl-phenyl)-2-methyl-8*H*-1,3a,7,8-tetraaza-cyclopenta[*a*]inden-3-ylmethyl]-(2-methoxy-1-methoxymethyl-ethyl)-amine.
- 18. A method of treating depression, anxiety, affective disorders, post-traumatic stress disorder, post-operative stress, headache, drug addiction, eating
  disorders and obesity, sudden death due to cardiac disorders, irritable bowel syndrome, hypertension, syndrome X, inflammatory disorders, stress-induced immune suppression, infertility, stress-induced insomnia and other sleep disorders, seizures, epilepsy, stroke and cerebral ischemia, traumatic brain injury, yet other disorders requiring neuroprotection, drug or alcohol
  withdrawal symptoms, other disorders including tachycardia, congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, ulcers, diarrhea and post-operative ileus comprising the administration of a pharmaceutical composition comprising a compound according to claim 1.